Patent application number | Description | Published |
20090131859 | FLOW PULSATILITY DAMPENING DEVICES FOR CLOSED-LOOP CONTROLLED INFUSION SYSTEMS - A flow monitoring infusion system that includes an infusion circuit having a fluid with a pulsatile fluid flow flowing therethrough. The infusion circuit includes a dampening element having a dampening chamber that absorbs the pressure fluctuations of the pulsatile fluid flow to transform the pulsatile fluid flow to a more smooth fluid flow. A fluid flow sensor that measures the flowrate of the more smooth fluid flow is disposed along the infusion circuit downstream of the dampening element. | 05-21-2009 |
20090218277 | SEPARATION APPARATUS AND METHOD - A separation apparatus and method are employed using a separation channel for rotation about an axis. Such channel includes radially spaced apart inner and outer side wall portions and an end wall portion. An inlet conveys fluid into the channel. A barrier is located in the channel intermediate of the inner and outer side wall portions. A first flow path communicates between upstream and downstream sides of the barrier. A collection region may be located downstream of the barrier for communication with the first flow path. An outer side wall section of the channel may be positioned radially outward of an upstream section thereof. The barrier may join the outer side wall portion along a substantial portion of an axial length of the channel. First and second exit flow paths may allow communication with the channel either upstream or downstream of the barrier or both. | 09-03-2009 |
20090275881 | OPTIMIZING THERAPY OUTCOMES FOR PERITONEAL DIALYSIS - Peritoneal dialysis therapy outcomes have been calculated for a variety of dwell times of peritoneal dialysis fluids in the peritoneal cavities of dialysis patients using kinetic modeling. The length of dwell time should not be the same for every patient, but should vary according to the patient condition and needs. Some patients have a potential for expressing greater ultrafiltrate into the dialysis fluid, and these patients can benefit from a longer dwell time, whereas other patients with less potential will not benefit from a longer dwell time. An optimal or peak time is observed for each peritoneal dialysis therapy outcome, such as ultrafiltrate volume rate, urea clearance (Kt/V), and creatinine clearance, while minimizing hydrocarbon absorption. These values and input parameters can be used to tailor the peritoneal dialysis dwell time for each patient, estimating the peak dwell time that will yield the best therapy outcome for each patient. | 11-05-2009 |
20100217178 | PREDICTION OF PERITONEAL DIALYSIS THERAPY OUTCOMES USING DIALYSATES MIXED AT DIFFERENT GLUCOSE CONCENTRATIONS - A method for peritoneal dialysis treatment includes (i) predicting results of a plurality of patient therapy outcomes for a plurality of different mixed dextrose level dialysis solutions; (ii) selecting one of the mixed dextrose level solutions for a patient based on the results; and (iii) performing at least one therapy using different unmixed dextrose level solutions that combine to simulate a like cumulative concentration that would be achieved using the selected mixed dextrose level solution. | 08-26-2010 |
20100217180 | SIMULATION OF PATIENT DRAIN PHASE IN PERITONEAL DIALYSIS - A method of modeling a patient's peritoneal dialysis drain phase includes (i) modeling a first segment of a drain phase curve as having a constant flowrate; (ii) modeling a second segment of a drain phase curve as having a decaying exponential flowrate; and (iii) incorporating a switching component into the first and second components so that (a) at a first time the first segment is active and while the second segment is inactive and (b) at a second time the first segment is inactive and while the second segment is active. | 08-26-2010 |
20110009810 | PERITONEAL DIALYSIS THERAPY WITH LARGE DIALYSIS SOLUTION VOLUMES - Patients suffering from acute renal failure must be diagnosed and treated quickly so that a physician can confidently prescribe either peritoneal dialysis or hemodialysis. In one way of quickly treating the patients, software is used to calculate a suitable peritoneal dialysis prescription without regard to how short or how long a dialysis cycle is used, and without regard to a total dialysate fluid volume for a therapy. For patients with suitable peritoneal membrane transport properties, the software program suggests that, at least over a short period of time, unexpectedly high ultrafiltrate volumes and high clearances may be achieved. | 01-13-2011 |
20110010101 | SIMPLIFIED PERITONEAL EQUILIBRATION TEST FOR PERITONEAL DIALYSIS - A simplified peritoneal equilibration test (S-PET) is disclosed. Instead of a lengthy peritoneal equilibration test (PET), the simplified procedure requires no blood sample and may use data from as few as two or three samples to classify a peritoneal membrane of a user. Typically, a peritoneal membrane or peritoneum of a dialysis patient, or other person, is classed as a high transport membrane, high-average transport membrane, a low-average transport membrane or a low transporter membrane. The S-PET may be performed at home by a user without the need to submit a blood sample. Kits for analyzing the samples may be furnished for home use. The kits may use disposable strips, microfluidic analyzers or chemical reagents, or may alternatively include reusable analysis equipment, such as optical or conductivity analysis equipment. | 01-13-2011 |
20110257891 | THERAPY PREDICTION AND OPTIMIZATION FOR RENAL FAILURE BLOOD THERAPY, ESPECIALLY HOME HEMODIALYSIS - A method of predicting serum phosphorus concentrations in a patient during hemodialysis includes measuring serum phosphorus concentrations of the patient over a hemodialysis treatment session time and an ultrafiltration rate calculated by a difference between pre- and post-dialytic body weight of the patient during an initial hemodialysis treatment session divided by a total treatment time of the treatment session and estimating a phosphorous mobilization clearance and a pre-dialysis distribution volume of phosphorus for the patient. Serum phosphorus concentrations of the patient can then be predicted at any time during any hemodialysis treatment session with the estimated phosphorous mobilization clearance and pre-dialysis distribution volume of phosphorus of the patient. | 10-20-2011 |
20120029324 | THERAPY PREDICTION AND OPTIMIZATION FOR RENAL FAILURE BLOOD THERAPY, ESPECIALLY HOME HEMODIALYSIS - A method of predicting serum phosphorus concentrations in a patient during hemodialysis includes measuring serum phosphorus concentrations of the patient over a hemodialysis treatment session time and an ultrafiltration rate calculated by a difference between pre- and post-dialytic body weight of the patient during an initial hemodialysis treatment session divided by a total treatment time of the treatment session and estimating a phosphorous mobilization clearance and a pre-dialysis distribution volume of phosphorus for the patient. Serum phosphorus concentrations of the patient can then be predicted at any time during any hemodialysis treatment session with the estimated phosphorous mobilization clearance and pre-dialysis distribution volume of phosphorus of the patient. | 02-02-2012 |
20130317795 | SIMULATION OF PATIENT DRAIN PHASE IN PERITONEAL DIALYSIS - A method of modeling a patient's peritoneal dialysis drain phase includes (a) modeling a first segment of a drain phase curve as having a constant flowrate, (b) modeling a second segment of the drain phase curve as having a decaying exponential flowrate, and (c) ensuring that a drain flowrate does not fall below a certain level during therapy by incorporating a switching component so that (i) at a first time the first segment is active while the second segment is inactive and (ii) at a second time the first segment is inactive while the second segment is active. | 11-28-2013 |
20140042092 | THERAPY PREDICTION AND OPTIMIZATION OF SERUM POTASSIUM FOR RENAL FAILURE BLOOD THERAPY, ESPECIALLY HOME HEMODIALYSIS - A method of predicting serum potassium concentrations in a patient during hemodialysis includes measuring serum potassium concentrations of the patient over a hemodialysis treatment session time and an ultrafiltration rate calculated by a difference between pre- and post-dialytic body weight of the patient during an initial hemodialysis treatment session divided by a total treatment time of the treatment session and estimating a potassium mobilization clearance and a pre-dialysis distribution volume of potassium for the patient. Serum potassium concentrations of the patient can then be predicted at any time during any hemodialysis treatment session with the estimated potassium mobilization clearance and pre-dialysis distribution volume of potassium of the patient. | 02-13-2014 |
20150032043 | THERAPY PREDICTION AND OPTIMIZATION FOR RENAL FAILURE BLOOD THERAPY, ESPECIALLY HOME HEMODIALYSIS - A renal failure blood therapy system includes a renal failure blood therapy machine, a test including multiple blood samples taken at multiple times during a test therapy to determine concentration levels for each of a first solute and a second solute at each of the multiple times, and a device programmed to (i) estimate at least one first patient parameter using the determined concentration levels for the first solute, (ii) estimate at least one second patient parameter using the determined concentration levels for the second solute, (iii) determine a first plurality of acceptable treatments using the at least one first patient parameter, (iv) determine a second plurality of acceptable treatments using the at least one second patient parameter, and (v) merge the first plurality of acceptable treatments with the second plurality of acceptable treatments to determine a plurality of clinically acceptable treatments for both the first solute and the second solute. | 01-29-2015 |
Patent application number | Description | Published |
20110302027 | COMMUNICATION AVAILABLE TRANSPORT NETWORK BANDWIDTH TO L2 ETHERNET NODES - Various embodiments relate to a communications system and related method of advertising available bandwidth capacities of leased links. After leasing a link to an operator device, a provider or operator may monitor the available capacity of the leased link and generate an advertising frame when the actual available capacity is below the defined leased capacity of the link. The advertising frame may be an L2 Ethernet frame in a form similar to the routing protocol used in the communications network to avoid additional strain and complexity in the network due to additional protocols for traffic engineering. After propagating the new information throughout the network using the advertising frame operator devices may redirect or shape their traffic of data in response to the updated available capacity on the leased link. | 12-08-2011 |
20120224495 | IN-SERVICE THROUGHPUT TESTING IN DISTRIBUTED ROUTER/SWITCH ARCHITECTURES - Various embodiments relate to a system and related method of measuring at least one transport link's performance in a communications network. An originating device controlled by a customer may generate testing frames that are transported to a receiving device also controlled by the customer through the at least one transport link that connects the two devices. In some embodiments, the transport links may transfer the testing frames while the transport links are transporting other data traffic. The receiving device may parse incoming frames and, upon identifying the testing frames, may generate echoing response frames. In some embodiments, the echoing response frames may be placed in one of a series of priority-based service queues. The originating device may then receive the response frames through the transport links and may measure the stream of incoming frames to measure and analyze the transport links' performance. | 09-06-2012 |
20130286874 | IN-SERVICE THROUGHPUT TESTING IN DISTRIBUTED ROUTER/SWITCH ARCHITECTURES - Various embodiments relate to a system and related method of measuring at least one transport link's performance in a communications network. An originating device controlled by a customer may generate testing frames that are transported to a receiving device also controlled by the customer through the at least one transport link that connects the two devices. In some embodiments, the transport links may transfer the testing frames while the transport links are transporting other data traffic. The receiving device may parse incoming frames and, upon identifying the testing frames, may generate echoing response frames. In some embodiments, the echoing response frames may be placed in one of a series of priority-based service queues. The originating device may then receive the response frames through the transport links and may measure the stream of incoming frames to measure and analyze the transport links' performance. | 10-31-2013 |
20140112159 | CIRCUIT EMULATION SERVICE FOR CARRYING TIME DIVISION MULTIPLEXED SCADA TRAFFIC - Embodiments of the invention employ specially adapted P2MP and MP2P transmission techniques to communicate traffic of a TDM based SCADA system over an IP/MPLS based network. Advantageously, by specially adapting P2MP and MP2P transmission techniques to carry TDM based SCADA traffic over an IP/MPLS network, an existing TDM based SCADA system can be migrated to an IP/MPLS network and operated in an easy to manage and bandwidth efficient manner as compared to a solution that employs point-to-point connections between a SCADA master node and subsystems over an IP/MPLS network. Furthermore, since TDM based SCADA equipment would not need to be replaced with IP based SCADA equipment in such a migration, significant equipment and installation costs associated with such replacement can be avoided. | 04-24-2014 |
Patent application number | Description | Published |
20090221650 | Use of Pyridoxamine to Treat and/or Prevent Disease Processes - Methods for treating and/or preventing at least one symptom of a disorder associated with oxidative stress, carbonyl stress, or combinations thereof in a subject. In some embodiments, the methods include administering to the subject an effective amount of pyridoxamine, an analog or derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing. Also provided are methods for treating or preventing a nephropathy, acute renal injury, acute renal failure, or combinations thereof in a subject, and formulations adapted for intravenous administration comprising pyridoxamine, an analog or derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing. | 09-03-2009 |
20100240710 | Use of Pyridoxamine to Treat and/or Prevent Disease Processes - Methods for treating and/or preventing at least one symptom of a disorder associated with oxidative stress, carbonyl stress, or combinations thereof in a subject. In some embodiments, the methods include administering to the subject an effective amount of pyridoxamine, an analog or derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing. Also provided are methods for treating or preventing a nephropathy, acute renal injury, acute renal failure, or combinations thereof in a subject, and formulations adapted for intravenous administration comprising pyridoxamine, an analog or derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing. | 09-23-2010 |
20130065929 | Use of Pyridoxamine to Treat and/or Prevent Disease Processes - Methods for treating and/or preventing at least one symptom of a disorder associated with oxidative stress, carbonyl stress, or combinations thereof in a subject. In some embodiments, the methods include administering to the subject an effective amount of pyridoxamine, an analog or derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing. Also provided are methods for treating or preventing a nephropathy, acute renal injury, acute renal failure, or combinations thereof in a subject, and formulations adapted for intravenous administration comprising pyridoxamine, an analog or derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing. | 03-14-2013 |
20140296303 | Use of Pyridoxamine to Treat and/or Prevent Disease Processes - Methods for treating and/or preventing at least one symptom of a disorder associated with oxidative stress, carbonyl stress, or combinations thereof in a subject. In some embodiments, the methods include administering to the subject an effective amount of pyridoxamine, an analog or derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing. Also provided are methods for treating or preventing a nephropathy, acute renal injury, acute renal failure, or combinations thereof in a subject, and formulations adapted for intravenous administration comprising pyridoxamine, an analog or derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing. | 10-02-2014 |
Patent application number | Description | Published |
20120125014 | THERMO-ELECTRIC HEAT PUMP SYSTEMS - The invention is directed to an energy efficient thermoelectric heat pump assembly. The thermoelectric heat pump assembly preferably comprises two to nine thermoelectric unit layers capable of active use of the Peltier effect; and at least one capacitance spacer block suitable for storing heat and providing a delayed thermal reaction time of the assembly. The capacitance spacer block is thermally connected between the thermoelectric unit layers. The present invention further relates to a thermoelectric transport and storage devices for transporting or storing temperature sensitive goods, for example, vaccines, chemicals, biologicals, and other temperature sensitive goods. Preferably the transport or storage devices are configured and provide on-board energy storage for sustaining, for multiple days, at a constant-temperature, with an acceptable temperature variation band. | 05-24-2012 |
20140182310 | THERMO-ELECTRIC HEAT PUMP SYSTEMS - This invention relates to providing energy efficient thermo-electric heat pump systems for iso-thermal transport and storage, of perishable goods, such as vaccines, chemicals, biologicals, and other temperature sensitive goods. Also this invention relates to providing energy efficient iso-thermal transport and storage systems, of perishable goods, which are compact, light weight. This invention further relates to providing on-board energy storage for sustaining, for multiple days, the ability of such iso-thermal transport and storage systems to maintain temperature sensitive goods at a constant-temperature. | 07-03-2014 |
20140216060 | THERMO-ELECTRIC HEAT PUMP SYSTEMS - The invention is directed to an energy efficient thermoelectric heat pump assembly. The thermoelectric heat pump assembly preferably comprises two to nine thermoelectric unit layers capable of active use of the Peltier effect; and at least one capacitance spacer block suitable for storing heat and providing a delayed thermal reaction time of the assembly. The capacitance spacer block is thermally connected between the thermoelectric unit layers. The present invention further relates to a thermoelectric transport and storage devices for transporting or storing temperature sensitive goods, for example, vaccines, chemicals, biologicals, and other temperature sensitive goods. Preferably the transport or storage devices are configured and provide on-board energy storage for sustaining, for multiple days, at a constant-temperature, with an acceptable temperature variation band. | 08-07-2014 |
20140318153 | THERMO-ELECTRIC HEAT PUMP SYSTEMS - The disclosure is directed to an energy efficient thermal protection assembly. The thermal protection assembly can comprise three or more thermoelectric unit layers capable of active use of the Peltier effect; and at least one capacitance spacer block suitable for storing heat and providing a delayed thermal reaction time of the assembly. The capacitance spacer block is thermally connected between the thermoelectric unit layers. The present disclosure further relates to a thermoelectric transport and storage devices for transporting or storing temperature sensitive goods, for example, vaccines, chemicals, biologicals, and other temperature sensitive goods. The transport or storage device can be configured and provide on-board energy storage for sustaining, for multiple days, at a constant-temperature, with an acceptable temperature variation band. | 10-30-2014 |